Trial Profile
A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2385 Tablets
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs PT 2385 (Primary)
- Indications Renal cancer
- Focus Pharmacokinetics
- Sponsors Peloton Therapeutics
- 09 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 22 Sep 2015 New trial record